Table 2.

Predictors of response to GO.

Predictors of response to GO	Favorable cytogenetic risk Intermediate cytogenetic risk CBF mutated AML [t(8;21)/inv(16)/t(16.16)] 11q23/KMT2A rearrangements NPM1/FLT3-ITD mutated AML Signaling mutation-positive AML CD33_PGx6_score of 0 or higher de novo or relapsed/resistant APL
Uncertain predictive role on response to GO	CD33 expression level Multidrug resistance (MDR) mediated by ATP-dependent drug transporters such as P-glycoprotein Sensitivity to calicheamicin in vitro CD33 single-nucleotide polymorphism rs12459419 genotype
Unfavorable predictors of response to GO	Adverse cytogenetic risk CD33_PGx6_score less than 0 Overexpression of bcl-2 and bcl-x PI3K/AKT, MEK/ERK, and JAK/STAT in vitro activation